Evidence summaries: new medicines
'Evidence summaries: new medicines' are provided to help commissioners, budget holders and groups such as Area Prescribing Committees to make informed decisions and aid local planning on the introduction of key new medicines.
They are quality-assured summaries of the best available evidence for selected new medicines, or existing medicines with new indications or a new formulation, that are considered to be of significance to the NHS. The topics selected are medicines that have recently gone into the UK market, or medicines that may be marketed in the UK in the next 6-12 months.
The strengths and weaknesses of the relevant evidence are critically reviewed, but the ‘Evidence summaries: new medicines' are not formal NICE guidance.
The NHS Constitution gives patients the right to expect that decisions about the funding of medicines and treatments will be made rationally following a proper consideration of the evidence. Where there is no technology appraisal from NICE, these summaries help to ensure consistent access to evidence for decision-makers.
NICE has published an interim process statement setting out how we select topics and prepare the summaries.
The National Prescribing Centre (NPC) legacy website has an archive of the NPC's new medicines rapid reviews.
View published ´Evidence summaries: new medicines´
Evidence summaries: new medicines coming soon
| Title | Expected date of publication |
| Lisdexamfetamine for ADHD | May 2013 |
| Alogliptin for type 2 diabetes | May 2013 |
This page was last updated: 17 April 2013